Apolipoprotein B mRNA-editing enzyme, catalytic polypeptides (APOBECs) are cytosine
deaminases involved in innate and adaptive immunity. However, some APOBEC family …

The molecular landscape in non-muscle-invasive bladder cancer (NMIBC) is characterized
by large biological heterogeneity with variable clinical outcomes. Here, we perform an …

There is considerable evidence of a positive association between the incidence of type 2
diabetes mellitus (T2DM) and obesity with bladder cancer (BCa), with the link between …

Background The standard of care treatment for muscle-invasive bladder cancer (MIBC) is
radical cystectomy, which is typically preceded by neoadjuvant chemotherapy. However, the …

Background APOBEC-driven mutagenesis and functional positive selection of mutated
genes may synergistically drive the higher frequency of some hotspot driver mutations …

Bladder cancer (BC) is a prevalent urological tumor with high recurrence rates, requiring
long‐term monitoring. Although cystoscopy is the primary diagnostic method, its …

Recent whole-genome sequencing studies identified two novel recurrent mutations in the
enhancer region of GPR126 in urothelial bladder cancer (UBC) tumor samples. This …

Mutations at specific hotspots in non-coding regions of ADGRG6, PLEKHS1, WDR74,
TBC1D12 and LEPROTL1 frequently occur in bladder cancer (BC). These mutations could …

GPR126, PLEKHS1, LEPROTL1 and WDR74). Clinical relevance was assessed by
performing analyses of mutation frequencies across disease stages, association with clinical …

Flexible cystoscopy is the mainstay of bladder cancer detection but is an imperfect test which
is resource-intensive and invasive for patients. A focus of bladder cancer research has been …